Diethyldithiocarbamate complex with copper: The mechanism of action in cancer cells

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 12, 2012, Pages 1184-1192

  Skrott, Zdenek ^a   Cvek, Boris ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Copper; Disulfiram; JAMM domain; Proteasome

Indexed keywords

19S PROTEASOME; 20S PROTEASOME; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIS(DIETHYLDITHIOCARBAMATE)COPPER; BORTEZOMIB; CASPASE 3; COPPER COMPLEX; CYTOCHROME C; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; DRUG METABOLITE; LACTACYSTIN; METALLOPROTEIN; MG 262; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN P27; PROTEIN POH1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COMPLEX FORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; OXIDATIVE STRESS; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; COORDINATION COMPLEXES; COPPER; DITIOCARB; HUMANS; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84866466140     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762068     Document Type: Article

References (133)

1. Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; O'Brien, C.P. The status of disulfiram: a half of a century later. J. Clin. Psychopharmacol., 2006, 26, 290-302.
2. Vallari, R.C.; Pietruszko, R. Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram. Science, 1982, 216, 637-639.
3. Lewison, E.F. Spontaneous regression of breast cancer. Prog. Clin. Biol. Res., 1977, 12, 47-53.
4. Wattenberg, L.W. Inhibition of chemical carcinogenesis. J. Natl. Cancer. Inst., 1978, 60, 11-18.
5. Irving, C.C.; Tice, A.J.; Murphy, W.M. Inhibition of N-n-butyl-N-(4 hydroxybutyl)nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet. Cancer Res., 1979, 39, 3040-3043.
6. Irving, C.C.; Daniel, D.S.; Murphy, W.M. The effect of disulfiram on the carcinogenicity of N-butyl-N-(3-carboxypropyl)nitrosamine in the rat. Carcinogenesis, 1983, 4, 617-620.
7. Dufour, P.; Lang, J.M.; Giron, C.; Duclos, B.; Haehnel, P.; Jaeck, D.; Jung, J.M.; Oberling, F. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy, 1993, 6, 9-12.
8. Cvek, B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr. Cancer Drug Targets, 2011, 11, 332-337.
9. Schreck, R.; Meier, B.; Männel, D.N.; Dröge, W.; Baeuerle, P.A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med., 1992, 175, 1181-1194.
10. Lövborg, H.; Oberg, F.; Rickardson, L.; Gullbo, J.; Nygren, P.; Larsson, R. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int. J. Cancer., 2006, 118, 1577-1580.
11. Wang, W.; McLeod, H.L.; Cassidy, J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int. J. Cancer, 2003, 104, 504-511.
12. Loo, T.W.; Clarke, D.M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Inst., 2000, 92, 898-902.
13. Sauna, Z.E.; Peng, X.H.; Nandigama, K.; Tekle, S.; Ambudkar, S.V. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol., 2004, 65, 675-684.
14. Cho, H.J.; Lee, T.S.; Park, J.B.; Park, K.K.; Choe, J.Y.; Sin, D.I.; Park, Y.Y.; Moon, Y.S.; Lee, K.G.; Yeo, J.H.; Han, S.M.; Cho, Y.S.; Choi, M.R.; Park, N.G.; Lee, Y.S.; Chang, Y.C. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J. Biochem. Mol. Biol., 2007, 40, 1069-1076.
15. Shian, S.G.; Kao, Y.R.; Wu, F.Y.; Wu, C.W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol. Pharmacol., 2003, 64, 1076-1084.
16. Cen, D.; Brayton, D.; Shahandeh, B.; Meyskens, F.L. Jr; Farmer, P.J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem., 2004, 47, 6914-6920.
17. Chen, D.; Cui, Q.C.; Yang, H.; Dou, Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res., 2006, 66, 10425-10433.
18. Brar, S.S.; Grigg, C.; Wilson, K.S.; Holder, W.D. Jr; Dreau, D.; Austin, C.; Foster, M.; Ghio, A.J.; Whorton, A.R.; Stowell, G.W.; Whittall, L.B.; Whittle, R.R.; White, D.P.; Kennedy, T.P. Disulfiram inhibits activating transcription factor/cyclic AMPresponsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol. Cancer Ther., 2004, 3, 1049-1060.
19. Guo, X.; Xu, B.; Pandey, S.; Goessl, E.; Brown, J.; Armesilla, A.L.; Darling, J.L.; Wang, W. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett., 2010, 290, 104-113.
20. Xu, B.; Shi, P.; Fombon, I.S.; Zhang, Y.; Huang, F.; Wang, W.; Zhou, S. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cells Mol. Dis., 2011, in press.
21. Cvek, B.; Milacic, V.; Taraba, J.; Dou, Q.P. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J. Med. Chem., 2008, 51, 6256-6258.
22. Viola-Rhenals, M.; Rieber, M.S.; Rieber, M. Role of peroxidases, thiols and Bak/Bax in tumor cell susceptibility to Cu[DEDTC]2. Biochem. Pharmacol., 2007, 74, 841-850.
23. Chen, S.H.; Liu, S.H.; Liang, Y.C.; Lin, J.K.; Lin-Shiau, S.Y.; Oxidative stress and c-Jun-amino-terminal kinase activation involved in apoptosis of primary astrocytes induced by disulfiram-Cu(2+) complex. Eur. J. Pharmacol., 2001, 414, 177-188.
24. Chen, S.H.; Lin, J.K.; Liang, Y.C.; Pan, M.H.; Liu, S.H.; Lin-Shiau, S.Y. Involvement of activating transcription factors JNK, NF-kappaB, and AP-1 in apoptosis induced by pyrrolidine dithiocarbamate/Cu complex. Eur. J. Pharmacol., 2008, 594, 9-17.
25. Daniel, K.G.; Chen, D.; Orlu, S.; Cui, Q.C.; Miller, F.R.; Dou, Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res., 2005, 7, R897-R908.
26. Chen, D.; Peng, F.; Cui, Q.C.; Daniel, K.G.; Orlu, S.; Liu, J.; Dou, Q.P. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front. Biosci., 2005, 10, 2932-2939.
27. Chen, Y.W.; Chen, K.L.; Chen, C.H.; Wu, H.C.; Su, C.C.; Wu, C.C.; Way, T.D.; Hung, D.Z.; Yen, C.C.; Yang, Y.T.; Lu, T.H. Pyrrolidine dithiocarbamate (PDTC)/Cu complex induces lung epithelial cell apoptosis through mitochondria and ER-stress pathways. Toxicol. Lett., 2010, 199, 333-340.
28. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl., 1992, 369, 15-26.
29. Hogarth, G. In: Progress in Inorganic Chemistry; Kenneth. D. Karlin,Ed; John Wiley & Sons, Inc.: NJ, USA, 2005; Vol. 53, pp. 71-561.
30. Cocco, D.; Calabrese, L.; Rigo, A.; Argese, E.; Rotilio, G. Reexamination of the reaction of diethyldithiocarbamate with the copper of superoxide dismutase. J. Biol. Chem., 1981, 256, 8983-8986.
31. Misra, H.P. Reaction of copper-zinc superoxide dismutase with diethyldithiocarbamate. J. Biol. Chem., 1979, 254, 11623-11628.
32. Johansson, B.; Stankiewicz, Z. Bis-(diethyldithiocarbamato) copper complex: a new metabolite of disulfiram? Biochem. Pharmacol., 1985, 34, 2989-2991.
33. Nelson, L.; Lewin, N.; Howland, M.A.; Hoffman, R.; Goldfrank, L.; Flomenbaum, N. Goldfrank's Toxicologic Emergencies, 9thed.; McGraw-Hill: New York, 2010.
34. Suzuki, Y.; Fujii, S.; Tominaga, T.; Yoshimoto, T.; Yoshimura, T.; Kamada, H. The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines. Biochim. Biophys. Acta, 1997, 1335, 242-245.
35. Tonkin, E.G.; Valentine, H.L.; Milatovic, D.M.; Valentine, W.M. N,N-diethyldithiocarbamate produces copper accumulation, lipid peroxidation, and myelin injury in rat peripheral nerve. Toxicol. Sci., 2004, 81, 160-171.
36. Delmaestro, E.; Trombetta, L.D. The effects of disulfiram on the hippocampus and cerebellum of the rat brain: a study on oxidative stress. Toxicol. Lett., 1995, 75, 235-243.
37. Szerdahelyi, P.; Kása, P. Regional differences in the uptake of exogenous copper into rat brain after acute treatment with sodium diethyldithiocarbamate. A histochemical and atomic absorption spectrophotometric study. Histochemistry, 1987, 86, 627-632.
38. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. Copper in diseases and treatments, and copper-based anticancer strategies. Med. Res. Rev., 2010, 30, 708-749.
39. Cvek, B.; Dvorak, Z. Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr. Pharm. Des., 2007, 13, 3155-3167.
40. Valko, M.; Morris, H.; Cronin, M.T. Metals, toxicity and oxidative stress. Curr. Med. Chem., 2005, 12, 1161-1208.
41. Cen, D.; Gonzalez, R.I.; Buckmeier, J.A.; Kahlon, R.S.; Tohidian, N.B.; Meyskens, F.L. Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol. Cancer Ther., 2002, 1, 197-204.
42. Jomova, K.; Valko, M. Advances in metal-induced oxidative stress and human disease. Toxicology, 2011, 283, 65-87.
43. Heikkila, R.E.; Cabbat, F.S.; Cohen, G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J. Biol. Chem., 1976, 251, 2182-2185.
44. Forman, H.J.; York, J.L.; Fisher, A.B. Mechanism for the potentiation of oxygen toxicity by disulfiram. J. Pharmacol. Exp. Ther., 1980, 212, 452-455.
45. Marikovsky, M.; Nevo, N.; Vadai, E.; Harris-Cerruti, C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int. J. Cancer, 2002, 97, 34-41.
46. Didion, S.P.; Hathaway, C.A.; Faraci, F.M. Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H1697-H1703.
47. Qiu, L.; Ding, L.; Huang, J.; Wang, D.; Zhang, J.; Guo, B. Induction of copper/zinc-superoxide dismutase by CCL5/CCR5 activation causes tumour necrosis factor-alpha and reactive oxygen species production in macrophages. Immunology, 2009, 128(1 Suppl), e325-e334.
48. Siwik, D.A.; Tzortzis, J.D.; Pimental, D.R.; Chang, D.L.; Pagano, P.J.; Singh, K.; Sawyer, D.B.; Colucci, W.S. Inhibition of copperzinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ. Res., 1999, 85, 147-53.
49. Li, J.; Li, P.F.; Dietz, R.; von Harsdorf, R. Intracellular superoxide induces apoptosis in VSMCs: role of mitochondrial membrane potential, cytochrome C and caspases. Apoptosis, 2002, 7, 511-517.
50. Huang, P.; Feng, L.; Oldham, E.A.; Keating, M.J.; Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature, 2000, 407, 390-395.
51. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med., 2010, 48, 749-762.
52. Circu, M.L.; Aw, T.Y. Glutathione and apoptosis. Free Radic. Res. 2008, 42, 689-706.
53. Ohno, Y.; Hirota, K.; Kawanishi, T.; Takanaka, A. Loss of viability after disulfiram treatment without preceding depletion of intracellular GSH. J. Toxicol. Sci., 1990, 15, 63-73.
54. Nagendra, S.N.; Shetty, K.T.; Rao, K.M.; Rao, B.S. Effect of disulfiram administration on rat brain glutathione metabolism. Alcohol, 1994, 11, 7-10.
55. Ningaraj, N.S.; Rao, M.K. Disulfiram augments oxidative stress in rat brain following bilateral carotid artery occlusion. J. Biomed. Sci., 1998, 5, 226-230.
56. Jin, L.; Davis, M.R.; Hu, P.; Baillie, T.A. Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. Evidence for metabolic activation of disulfiram in vivo. Chem. Res. Toxicol., 1994, 7, 526-533.
57. Di Nicuolo, F.; Serini, S.; Boninsegna, A.; Palozza, P.; Calviello, G. Redox regulation of cell proliferation by pyrrolidine dithiocarbamate in murine thymoma cells transplanted in vivo. Free Radic. Biol. Med., 2001, 31, 1424-1431.
58. Grosicka-Maciag, E.; Kurpios-Piec, D.; Grzela, T.; Czeczot, H.; Skrzycki, M.; Szumiło, M.; Rahden-Staroń, I. Protective effect of Nacetyl-L-cysteine against disulfiram-induced oxidative stress and apoptosis in V79 cells. Toxicol. Appl. Pharmacol., 2010, 248, 210-216.
59. Somers, P.K.; Medford, R.M.; Saxena, U. Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Radic. Biol. Med., 2000, 28, 1532-1537.
60. Nathens, A.B.; Bitar, R.; Davreux, C.; Bujard, M.; Marshall, J.C.; Dackiw, A.P.; Watson, R.W.; Rotstein, O.D. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am. J. Respir. Cell. Mol. Biol., 1997, 17, 608-616.
61. Szotowski, B.; Antoniak, S.; Goldin-Lang, P.; Tran, Q.V.; Pels, K.; Rosenthal, P.; Bogdanov, V.Y.; Borchert, H.H.; Schultheiss, H.P.; Rauch, U. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc. Res., 2007, 73, 806-812.
62. Erl, W.; Weber, C.; Hansson, G.K. Pyrrolidine dithiocarbamateinduced apoptosis depends on cell type, density, and the presence of Cu(2+) and Zn(2+). Am. J. Physiol. Cell. Physiol., 2000, 278, C1116-C1125.
63. Kim, C.H.; Kim, J.H.; Moon, S.J.; Hsu, C.Y.; Seo, J.T.; Ahn, Y.S. Biphasic effects of dithiocarbamates on the activity of nuclear factor-kappaB. Eur. J. Pharmacol., 2000, 392, 133-136.
64. Navrátilová, J.; Jungová, P.; Vanhara, P.; Preisler, J.; Kanicky, V.; Smarda, J. Copper ions regulate cytotoxicity of disulfiram to myeloid leukemia cells. Int. J. Mol. Med., 2009, 24, 661-670.
65. Oh da, H.; Bang, J.S.; Choi, H.M.; Yang, H.I.; Yoo, M.C.; Kim, K.S. Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells. Eur. J. Pharmacol., 2010, 649, 135-139.
66. Speisky, H.; Gómez, M.; Carrasco-Pozo, C.; Pastene, E.; Lopez-Alarcón, C.; Olea-Azar, C. Cu(I)-glutathione complex: a potential source of superoxide radicals generation. Bioorg. Med. Chem., 2008, 16, 6568-6574.
67. Speisky, H.; Gómez, M.; Burgos-Bravo, F.; López-Alarcón, C.; Jullian, C.; Olea-Azar, C.; Aliaga, M.E. Generation of superoxide radicals by copper-glutathione complexes: redox-consequences associated with their interaction with reduced glutathione. Bioorg. Med. Chem., 2009, 17, 1803-1810.
68. Aliaga, M.E.; López-Alarcón, C.; Barriga, G.; Olea-Azar, C.; Speisky, H. Redox-active complexes formed during the interaction between glutathione and mercury and/or copper ions. J. Inorg. Biochem., 2010, 104, 1084-1090.
69. Hansen, J.M.; Zhang, H.; Jones, D.P. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic. Biol. Med., 2006, 40, 138-145.
70. Franco, R.; Cidlowski, J.A. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ., 2009, 16, 1303-1314.
71. Franco, R.; Panayiotidis, M.I.; Cidlowski, J.A. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J. Biol. Chem., 2007, 282, 30452-30465.
72. Chen, S.H.; Liu, S.H.; Liang, Y.C.; Lin, J.K.; Lin-Shiau, S.Y. Death signaling pathway induced by pyrrolidine dithiocarbamate-Cu(2+) complex in the cultured rat cortical astrocytes. Glia, 2000, 31, 249-261.
73. Zafarullah, M.; Li, W.Q.; Sylvester, J.; Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol. Life Sci., 2003, 60, 6-20.
74. Jomova, K.; Vondrakova, D.; Lawson, M.; Valko, M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem., 2010, 345, 91-104.
75. Spasojević, I.; Mojović, M.; Stević, Z.; Spasić, S.D.; Jones, D.R.; Morina, A.; Spasić, M.B. Bioavailability and catalytic properties of copper and iron for Fenton chemistry in human cerebrospinal fluid. Redox Rep., 2010, 15, 29-35.
76. Rae, T.D.; Schmidt, P.J.; Pufahl, R.A.; Culotta, V.C.; O'Halloran, T.V. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science, 1999, 284, 805-808.
77. Schrader, E.K.; Harstad, K.G.; Matouschek, A. Targeting proteins for degradation. Nat. Chem. Biol., 2009, 5, 815-822.
78. Pickart, C.M.; Cohen, R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol., 2004, 5, 177-187.
79. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem., 2009, 78, 477-513.
80. Cvek, B.; Dvorak, Z. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr. Pharm. Des., 2011, 17, 1483-1499.
81. Goldberg, A.L. Protein degradation and protection against misfolded or damaged proteins. Nature, 2003, 426, 895-899.
82. Shang, F.; Taylor, A. Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free Radic. Biol. Med., 2011, 51, 5-16.
83. Grune, T.; Catalgol, B.; Licht, A.; Ermak, G.; Pickering, A.M.; Ngo, J.K.; Davies, K.J. HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic. Biol. Med., 2011, 51, 1355-1364.
84. Jung, T.; Grune, T. The proteasome and its role in the degradation of oxidized proteins. IUBMB Life, 2008, 60, 743-752.
85. Milacic, V.; Chen, D.; Giovagnini, L.; Diez, A.; Fregona, D.; Dou, Q.P. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol. Appl. Pharmacol., 2008, 231, 24-33.
86. Xiao, Y.; Chen, D.; Zhang, X.; Cui, Q.; Fan, Y.; Bi, C.; Dou, Q.P. Molecular study on copper-mediated tumor proteasome inhibition and cell death. Int. J. Oncol., 2010, 37, 81-87.
87. Berges, C.; Haberstock, H.; Fuchs, D.; Sadeghi, M.; Opelz, G.; Daniel, V.; Naujokat, C. Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells. J. Cell. Biochem., 2009, 108, 935-946.
88. Du, Z.X.; Zhang, H.Y.; Meng, X.; Guan, Y.; Wang, H.Q. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer, 2009, 9, 56.
89. Fribley, A.; Zeng, Q.; Wang, C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in headand neck squamous cell carcinoma cells. Mol. Cell Biol., 2004, 24, 9695-9704.
90. Ling, Y.H.; Liebes, L.; Zou, Y.; Perez-Soler, R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem., 2003, 278, 33714-33723.
91. Pérez-Galán, P.; Roué, G.; Villamor, N.; Montserrat, E.; Campo, E.; Colomer, D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.
92. Yu, C.; Rahmani, M.; Dent, P.; Grant, S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp. Cell Res., 2004, 295, 555-566.
93. Han, Y.H.; Park, W.H. The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death. Chem. Biol. Interact., 2010, 184, 319-327.
94. Han, Y.H.; Moon, H.J.; You, B.R.; Kim, S.Z.; Kim, S.H.; Park, W.H. The effects of N-acetyl cysteine on the MG132 proteasome inhibitor-treated lung cancer cells in relation to cell growth, reactive oxygen species and glutathione. Int. J. Mol. Med., 2010, 25, 657-662.
95. Wu, H.M.; Chi, K.H.; Lin, W.W. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett., 2002, 526, 101-105.
96. Lee, M.H.; Hyun, D.H.; Jenner, P.; Halliwell, B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J. Neurochem., 2001, 78, 32-41.
97. Qiu, J.H.; Asai, A.; Chi, S.; Saito, N.; Hamada, H.; Kirino, T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci., 2000, 20, 259-625.
98. Papa, L.; Gomes, E.; Rockwell, P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis, 2007, 12, 1389-1405.
99. Zou, W.; Yue, P.; Lin, N.; He, M.; Zhou, Z.; Lonial, S.; Khuri, F.R.; Wang, B.; Sun, S.Y. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin. Cancer Res., 2006, 12, 273-280.
100. Meusser, B.; Hirsch, C.; Jarosch, E.; Sommer, T. ERAD: the long road to destruction. Nat. Cell Biol., 2005, 7, 766-772.
101. Vembar, S.S.; Brodsky, J.L. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol., 2008, 9, 944-957.
102. Rasheva, V.I.; Domingos, P.M. Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis, 2009, 14, 996-1007.
103. Heath-Engel, H.M.; Chang, N.C.; Shore, G.C. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene, 2008, 27, 6419-6433.
104. Obeng, E.A.; Carlson, L.M.; Gutman, D.M.; Harrington, W.J. Jr.; Lee, K.P.; Boise, L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 2006, 107, 4907-4916.
105. Nawrocki, S.T.; Carew, J.S.; Maclean, K.H.; Courage, J.F.; Huang, P.; Houghton, J.A.; Cleveland, J.L.; Giles, F.J.; McConkey, D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood, 2008, 112, 2917-2926.
106. Nawrocki, S.T.; Carew, J.S.; Pino M.S.; Highshaw, R.A.; Dunner, K. Jr.; Huang, P.; Abbruzzese, J.L.; McConkey, D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stressmediated apoptosis. Cancer Res., 2005, 65, 11658-11666.
107. Nawrocki, S.T.; Carew, J.S.; Dunner, K. Jr.; Boise, L.H.; Chiao, P.J.; Huang, P.; Abbruzzese, J.L.; McConkey, D.J. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res., 2005, 65, 11510-11519.
108. Landowski, T.H.; Megli, C.J.; Nullmeyer, K.D.; Lynch, R.M.; Dorr, R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade(PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res., 2005, 65, 3828-3836.
109. Lee, A.H.; Iwakoshi, N.N.; Anderson, K.C.; Glimcher, L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 9946-9951.
110. Morgillo, F.; D'Aiuto, E.; Troiani, T.; Martinelli, E.; Cascone, T.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer, 2011, 71, 283-290.
111. Tardito, S.; Bassanetti, I.; Bignardi, C.; Elviri, L.; Tegoni, M.; Mucchino, C.; Bussolati, O.; Franchi-Gazzola, R.; Marchiò, L. Copper binding agents acting as copper ionophores lead to caspase inhibition and paraptotic cell death in human cancer cells. J. Am. Chem. Soc., 2011, 133, 6235-6242.
112. Hancock, C.N.; Stockwin, L.H.; Han, B.; Divelbiss, R.D.; Jun, J.H.; Malhotra, S.V.; Hollingshead, M.G.; Newton, D.L. A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic. Biol. Med., 2011, 50, 110-121.
113. Tardito, S.; Isella, C.; Medico, E.; Marchiò, L.; Bevilacqua, E.; Hatzoglou, M.; Bussolati, O.; Franchi-Gazzola, R. The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J. Biol. Chem., 2009, 284, 24306-24319.
114. Hoeller, D.; Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature, 2009, 458, 438-444.
115. Cvek, B.; Dvorak, Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov. Today, 2008, 13, 716-722.
116. Verma, R.; Aravind, L.; Oania, R.; McDonald, W.H.; Yates, J.R. 3rd; Koonin, E.V.; Deshaies, R.J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science, 2002, 298, 611-615.
117. Yao, T.; Cohen, R.E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature, 2002, 419, 403-407.
118. Gallery, M.; Blank, J.L.; Lin, Y.; Gutierrez, J.A.; Pulido, J.C.; Rappoli, D.; Badola, S.; Rolfe, M.; Macbeth, K.J. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol. Cancer Ther., 2007, 6, 262-268.
119. Byrne, A.; McLaren, R.P.; Mason, P.; Chai, L.; Dufault, M.R.; Huang, Y.; Liang, B.; Gans, J.D.; Zhang, M.; Carter, K.; Gladysheva, T.B.; Teicher, B.A.; Biemann, H.P.; Booker, M.; Goldberg, M.A.; Klinger, K.W.; Lillie, J.; Madden, S.L.; Jiang, Y. Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. Exp. Cell Res., 2010, 316, 258-271.
120. Cope, G.A.; Suh, G.S.; Aravind, L.; Schwarz, S.E.; Zipursky, S.L.; Koonin, E.V.; Deshaies, R.J. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science, 2002, 298, 608-611.
121. Richardson, K.S.; Zundel, W. The emerging role of the COP9 signalosome in cancer. Mol. Cancer Res., 2005, 3, 645-653.
122. Tomoda, K.; Kubota, Y.; Kato, J. Degradation of the cyclindependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature, 1999, 398, 160-165.
123. Adler, A.S.; Littlepage, L.E.; Lin, M.; Kawahara, T.L.; Wong, D.J.; Werb, Z.; Chang, H.Y. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res., 2008, 68, 506-515.
124. Eldridge, A.G.; O'Brien, T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ., 2010, 17, 4-13.
125. Fraile, J.M.; Quesada, V.; Rodríguez, D.; Freije, J.M.; López-Otín, C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene, 2011, in press.
126. Bedford, L.; Lowe, J.; Dick, L.R.; Mayer, R.J.; Brownell, J.E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov., 2011, 10, 29-46.
127. D'Arcy, P.; Brnjic, S.; Olofsson, M.H.; Fryknäs, M.; Lindsten, K.; De Cesare, M.; Perego, P.; Sadeghi, B.; Hassan, M.; Larsson, R.; Linder, S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med., 2011, in press.
128. Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.; Nelson, W.G.; Yegnasubramanian, S.; Carducci, M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate, 2011, 71, 333-343.
129. R Kona, F.; Buac, D.; M Burger, A. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies. Curr. Cancer Drug Targets, 2011, 11, 338-346.
130. Boguski, M.S.; Mandl, K.D.; Sukhatme, V.P. Drug discovery. Repurposing with a difference. Science, 2009, 324, 1394-1395.
131. Chong, C.R.; Sullivan, D.J. Jr. New uses for old drugs. Nature, 2007, 448, 645-646.
132. Collins, F.S. Mining for therapeutic gold. Nat. Rev. Drug Discov, 2011, 10, 397.
133. Cvek, B. Antabuse (disulfiram) as a pilot case of nonprofit drug. Int. J. Cancer, 2010, 127, 2486.